AMGN vs ZYME · P/E 24, rev $36.75B vs rev $76.3M
Amgen Inc (AMGN) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the AMGN and ZYME stock pages for the full models.
Not investment advice.